Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

被引：0
|
作者：
Zhou, Qing
Yang, Nong
Zhao, Jun
Dong, Xiaorong
Wang, Huijuan
Yuan, Ying
Yu, Yan
Zhang, Meijiang
Zhang, Sujie
Huang, Mengna
Shen, Yuping
Wu, Yi-Long
机构：
[1] Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Hunan Canc Hosp, Changsha, Peoples R China
[3] Beijing Canc Hosp, Beijing, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongi Med Coll, Wuhan, Peoples R China
[5] Henan Canc Hosp, Zhengzhou, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Zhejiang, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[8] Innovent Biol Inc, Suzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3110
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [32] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [33] A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.
    Im, Seock-Ah
    Lee, SeungHwan
    Lee, Keun Wook
    Lee, Youngjoo
    Sohn, Joohyuk
    Kim, Jee Hyun
    Im, Young-Hyuck
    Park, Kyong Hwa
    Oh, Do-Youn
    Kim, Min Hwan
    Park, Yeon Hee
    Kim, Tae Min
    Choi, Yoon Ji
    Lee, Chang-Seok
    Park, Jiseon
    Baek, Nam Seok
    Choi, MiKyung
    Kim, John
    Yu, Eunyoung
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] A phase I dose escalation and pharmacodynamic study of weekly administered AlbuleukinTM in patients with advanced solid tumors.
    Agarwala, SS
    Bukowski, RM
    Kirkwood, J
    Weiss, P
    Olencki, T
    Grzegorewski, KJ
    Melder, R
    Fox, RA
    Herpst, JM
    Gallant, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6230S - 6231S
  • [35] A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
    Gort, Eelke
    Johnson, Melissa Lynne
    Hwang, Jimmy J.
    Pant, Shubham
    Dunzinger, Ulrich
    Riemann, Kathrin
    Kitzing, Thomas
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors.
    Lickliter, Jason D.
    Jennens, Ross
    Lemech, Charlotte Rose
    Kichenadasse, Ganessan
    Cai, Dongpo
    Su, Steven Yung-Chang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A)
    Dillon, Magnus T.
    Espinasse, Aude
    Ellis, Sally
    Mohammed, Kabir
    Grove, Lorna G.
    McLellan, Lyndall
    Smith, Simon A.
    Ross, Graham
    Adeleke, Sola
    Woo, Kin
    Josephides, Eleni
    Spicer, James F.
    Forster, Martin D.
    Harrington, Kevin J.
    CANCER RESEARCH, 2017, 77
  • [38] A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
    LoRusso, Patricia
    Gounder, Mrinal M.
    Patel, Manish R.
    Yamamoto, Noboru
    Bauer, Todd Michael
    Laurie, Scott
    Grempler, Rolf
    Davenport, Teffany
    Geng, Junxian
    Rohrbacher, Maren
    Lahmar, Mehdi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [40] Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors.
    Tsai, Hui-Jen
    Chiang, Nai-Jung
    Shiah, Her-Shyong
    Chang, Kwang-Yu
    Su, Wu-Chou
    Chang, Jang-Yang
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345